These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8097097)

  • 1. Detection of zidovudine-resistant variants of HIV-1 in genital fluids.
    Wainberg MA; Beaulieu R; Tsoukas C; Thomas R
    AIDS; 1993 Mar; 7(3):433-4. PubMed ID: 8097097
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen.
    Anderson DJ; O'Brien TR; Politch JA; Martinez A; Seage GR; Padian N; Horsburgh CR; Mayer KH
    JAMA; 1992 May; 267(20):2769-74. PubMed ID: 1349654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy.
    Krieger JN; Coombs RW; Collier AC; Ross SO; Chaloupka K; Cummings DK; Murphy VL; Corey L
    J Infect Dis; 1991 Feb; 163(2):386-8. PubMed ID: 1988523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p24 antigenaemia and clinical response to zidovudine therapy.
    Montroni M; Silvestri G; Butini L; Regnery C; Bartocci C; Buffarini F; Danieli G
    AIDS; 1993 Mar; 7(3):434-5. PubMed ID: 8471208
    [No Abstract]   [Full Text] [Related]  

  • 5. Resolution of HIV retinitis with zidovudine therapy.
    Molina JM; Ferchal F; Marcel P; Morinet F; Modai J
    Am J Med; 1992 Dec; 93(6):700-2. PubMed ID: 1361303
    [No Abstract]   [Full Text] [Related]  

  • 6. Short-term evaluation of zidovudine-treated patients: decrease in plasma and cellular viraemia titres.
    Tamalet C; Masquelier B; Ferchal F; Agut H; Puel J; Brun-Vézinet F; Fleury H; Rouzioux C
    AIDS; 1992 Nov; 6(11):1403-4. PubMed ID: 1361750
    [No Abstract]   [Full Text] [Related]  

  • 7. Population dynamics of HIV within an individual after treatment with zidovudine.
    McLean AR; Emery VC; Webster A; Griffiths PD
    AIDS; 1991 May; 5(5):485-9. PubMed ID: 1677807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.
    Molina JM; Ferchal F; Chevret S; Barateau V; Poirot C; Morinet F; Modai J
    AIDS; 1994 Jan; 8(1):27-33. PubMed ID: 7912084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features of acute HIV-1 infection: zidovudine-resistant isolates compared with zidovudine-sensitive isolates.
    Vanhems P; Gaudet R; Hirschel B; Imrie A; Conway B; Rouleau D; Vizzard J; Perrin L; Cooper DA; Yerly S
    AIDS; 2000 May; 14(8):1065-7. PubMed ID: 10853993
    [No Abstract]   [Full Text] [Related]  

  • 10. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts.
    Angarano G; Monno L; Appice A; Giannelli A; Romanelli C; Fico C; Pastore G
    AIDS; 1994 Jul; 8(7):1013-4. PubMed ID: 7524541
    [No Abstract]   [Full Text] [Related]  

  • 11. Trend towards decreased survival in patients infected with HIV resistant to zidovudine.
    Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF
    Scand J Infect Dis; 1992; 24(5):563-5. PubMed ID: 1361240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus type 1 variants.
    Wahlberg J; Fiore J; Angarano G; Uhlén M; Albert J
    J Infect Dis; 1994 Mar; 169(3):611-4. PubMed ID: 8158034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments.
    Mbori-Ngacha D; Richardson BA; Overbaugh J; Panteleeff DD; Nduati R; Steele M; John-Stewart G
    J Virol; 2003 Jul; 77(13):7702-5. PubMed ID: 12805473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1.
    Kuritzkes DR; Bell S; Bakhtiari M
    AIDS; 1994 Jul; 8(7):1017-9. PubMed ID: 7524542
    [No Abstract]   [Full Text] [Related]  

  • 15. Primary infection with zidovudine-resistant HIV.
    Hermans P; Sprecher S; Clumeck N
    N Engl J Med; 1993 Oct; 329(15):1123; author reply 1124. PubMed ID: 8371738
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of zidovudine resistant variants of HIV-1 isolated from patients on prolonged therapy.
    Wainberg MA; Tremblay M; Rooke R; Fanning M; Tsoukas C; Montaner JS; O'Shaughnessy M; Ruedy J
    Drugs Exp Clin Res; 1992; 18(7):283-90. PubMed ID: 1295721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection.
    Frost SD; McLean AR
    AIDS; 1994 Mar; 8(3):323-32. PubMed ID: 7913327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Investigation of AZT sensitivity of HIV-1 isolates from patients treated with AZT].
    Saito T; Kondo M; Ito A; Nagao T; Imai M
    Kansenshogaku Zasshi; 1993 Apr; 67(4):311-4. PubMed ID: 8315299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary infection with zidovudine-resistant HIV.
    Masquelier B; Lemoigne E; Pellegrin I; Douard D; Sandler B; Fleury HJ
    N Engl J Med; 1993 Oct; 329(15):1123-4. PubMed ID: 8371739
    [No Abstract]   [Full Text] [Related]  

  • 20. Selective expansion of a minor proportion of drug-resistant HIV-1 by antiretroviral pressure in vitro.
    Roberts BD; Pau CP; Weinstock H; Heneine W; Butera ST
    AIDS; 2000 Dec; 14(17):2797-8. PubMed ID: 11125904
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.